Herantis Pharma Oyj
Herantis Pharma Oyj (HRPMF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hrpmf · pe ratio · data through Dec 31, 2024
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Herantis Pharma Oyj (HRPMF) measures how much investors pay for each dollar of the company's trailing earnings. HRPMF's current PE ratio of N/A is calculated by dividing its stock price of $3.51 by its TTM earnings per share of -$0.27.
Source: FMP · /ratios-ttm · /analyst-estimates · 2024-12-31
PE Ratio History
2011 – 2024 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Herantis Pharma OyjYou HRPMF | $59M | N/A | — | -$0.27 |
 Biostage, Inc. BSTG | $58M | N/A | — | -$0.42 |
 Small Pharma Inc. DMTTF | $38M | N/A | — | -$0.07 |
 Elegance Optical International Holdings Limited EEOIF | $63M | N/A | — | — |
 Goodness Growth Holdings, Inc. GDNSF | $61M | N/A | — | -$0.00 |
 Karolinska Development AB (publ) KDEVF | $69M | 129.97x | — | $0.02 |
 Mindset Pharma Inc. MSSTF | $55M | N/A | — | -$0.18 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2024-12-31Latest FY2024 | — | $-0.24 | — | |
2023-12-31 FY2023 | 195.12x | $0.02 | — | |
2022-12-31 FY2022 | — | $-0.64 | — | |
2021-12-31 FY2021 | — | $-2.31 | — | |
2020-12-31 FY2020 | — | $-1.24 | — | |
2019-12-31 FY2019 | — | $-1.30 | — | |
2018-12-31 FY2018 | — | $-0.85 | — | |
2017-12-31 FY2017 | — | $-0.51 | — | |
2016-12-31 FY2016 | — | $-1.02 | — | |
2015-12-31 FY2015 | — | $-3.75 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Herantis Pharma Oyj (HRPMF) measures how much investors pay for each dollar of the company's trailing earnings. HRPMF's current PE ratio of N/A is calculated by dividing its stock price of $3.51 by its TTM earnings per share of -$0.27.
Frequently asked questions
HRPMF pe ratio · 6 questionsHRPMF's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.51 and TTM EPS of -$0.27. Data sourced from Financial Modeling Prep via HRPMF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Herantis Pharma Oyj SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09